Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.

Slides:



Advertisements
Similar presentations
Adding Prandial Insulin to Basal Insulin: Key Challenges
Advertisements

What's New in Basal Insulin for Diabetes
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Faster-Acting Insulins
An Update on Oral Prostanoids: Advancing Care for PAH?
SGLT2 Inhibitors: What Do the Data Mean for My Patients?
New Patient-Friendly Options for Managing Insulin Dosing
Glaucoma Progression.
Modern Strategies for Basal Insulin Use in T2D
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Utilizing New Technologies and Insulins for a Tighter Grip on PPG
Insulin Innovation.
Insulin/GLP-1 Agonist Combinations
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.
Agenda. Insulin Intensification Strategies: An Expert Perspective from Asia-Pacific.
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Novel Concentrated Insulins: What Benefits and for Which Patients?
Optimizing Outcomes in the Management of GIST
Working as a Team for Improved Patient Outcomes in Type 2 Diabetes
Examining CV Effects of Basal Insulin Therapy
Clinical Cases in Glaucoma Treatment
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
GLP-1 Receptor Agonists: How Early Is Appropriate?
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
Faster-Acting Insulins
A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.
Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Insulin/GLP-1 Agonist Combinations
Insulin Use in Primary Care: Practice Challenges
Insulin Innovation.
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
LEADER One Year On.
GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?
T2DM Management.
Better Diabetes Control With Novel Basal Insulins
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
When Is Intrathecal Drug Delivery Appropriate?
Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?
Insulin Innovation.
PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
Add-On Therapy to Insulin in T1DM Management
Challenges in LA SCCHN.
Improving Adherence to Antiplatelet Therapy After an ACS Event
Deep Dive: Examining Emerging GLP-1 RAs From a Clinical Perspective
When Is Intrathecal Drug Delivery Appropriate?
Getting PPG Under Control
Emerging Combination Injectable Therapy A New Era in Diabetes Care
PAH Pathways: What Do the Data Tell Us?”
Championing Evidence-Based Care in Patients With Acute Low Back Pain
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future
Fixed-Ratio Combination Therapy in T2DM
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
Guideline approach to drug therapy in newly diagnosed type 2 diabetic patients not at target. Guideline approach to drug therapy in newly diagnosed type.
Fresh perspectives ON BASAL Insulins in diabetes care
Late-Breaking Data on LDL-C Reduction
In the Know.
The Challenge of Insulin Titration
Presentation transcript:

Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations

Program Overview

Clinical Inertia in Primary Care

Adding Insulin: Clinical Inertia

The Importance of Controlling PPG

Many Options for Intensifying T2DM Therapy

Challenge for Guideline Developers

Adherence to Injectable T2DM Therapy

Benefits of Adding GLP-1 RA to Insulin Therapy

Basal Insulin/GLP-1 RA: Fixed Ratio Combination

Clinical Trial Results: Glycemic Control

Future Use of Basal Insulin/GLP-1 RA

Patient Case 1: Profile

Patient Case 1: Profile (cont)

Patient Case 1: Glycemic Target

Patient Case 1: Treatment Options

Patient Case 1: Treatment Options (cont)

Patient Case 2: Profile

Patient Case 2: Profile (cont)

Patient Case 2: Treatment Options

Summary

Summary (cont)